This Request for Information (RFI) is not a solicitation for proposals, proposal abstracts, quotations, or obligation on the part of the Government to acquire any products or services, but for planning purposes only. The purpose of this RFI is to conduct market research to gain knowledge of potential qualified sources and to explore industry capabilities. Your response to this RFI will be treated as information only. No entitlement to payment of direct or indirect costs or charges by the Government will arise as a result of contractor submission to this announcement or the Government use of such information. The information provided may also be used by the United States Army Medical Research Acquisition Activity (USAMRAA) for market research in developing its acquisition strategy, statement of work/statement of objectives, and performance specifications. Interested parties are responsible for adequately marking proprietary or competition sensitive information contained in their response. The Government does not intend to award a contract based on this request for information or to otherwise pay for the information submitted in response to this RFI.

All responses to this RFI will be used by the United States Army Medical Research Acquisition Activity (USAMRAA) to identify potential sources to perform the following:

The Virology Division at USAMRIID (United States Army Medical Research Institute of Infectious Diseases), Fort Detrick, MD has a requirement to evaluate the immunogenicity of a novel vaccine platform administered in multiple formulations (28 or 56 days apart) by intramuscular (IM) injection to Cynomolgus macaques. The vendor must be capable of pre-screening, vaccinating and housing Cynomolgus macaques according to the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) recommendations, current requirements stated in the current quote mark Guide for Care and Use of Laboratory Animals quote mark and current requirements as stated by the U.S. Department of Agriculture through the Animal Welfare Act (as amended). The vendor must be capable of pre-screening all animals and confirm they are negative for the following pathogens: Filoviruses, Alphaviruses, tuberculosis, HMV phenotype of Klebsiella pneumoniae, shigella, salmonella, and Yersinia. The vendor must be able to collect whole blood in serum separator (SST), EDTA K2, Na citrate, and CPT Heparin collection tubes at various time points both pre- and post-vaccination of the animals. After blood collection, the vendor must be able to process each sample and aliquot accordingly for serum (SST), whole blood (EDTA K2), plasma (Na Citrate), and PBMCs (CPT Heparin) and ship the samples to USAMRIID for additional analysis. If during USAMRIID analysis, it is determined that the animals produced an adequate immune response to the vaccine, the vendor will ship the animals to USAMRIID for additional evaluation; if the animals do not produce an adequate response to the vaccine, then the vendor will dispose of the animals according to their own institute policies and procedures.



Once the information is received, USAMRAA may publish a synopsis requesting further information and industry comments on a refined set of requirements along with a draft acquisition strategy and milestone schedule.
Interested parties shall respond, no later than 14 April 2014 at 12pm Eastern Time, with a capabilities package that corresponds to your organization's technical capability to provide services that meet all of the aforementioned attributes. All responses shall be submitted by email to the Contract Specialist, Eric Olmstead @[email protected].

This announcement is a request for information sources sought only and does not constitute a Request for Proposals (RFP). An RFP may or may not be posted in the future. The Government does not guarantee any action beyond this RFI.
Contracting Office Address:

United States
Primary Point of Contact.:
Eric Olstead,
Contract Specialist
[email protected]

Bid Protests Not Available